{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:07:07Z","timestamp":1789495627276,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding of PUMCH","award":["(2022-PUMCH-B-128)"],"award-info":[{"award-number":["(2022-PUMCH-B-128)"]}]},{"name":"National High Level Hospital Clinical Research Funding of PUMCH","award":["(2022-PUMCH-B-128)"],"award-info":[{"award-number":["(2022-PUMCH-B-128)"]}]},{"name":"National High Level Hospital Clinical Research Funding of PUMCH","award":["(2022-PUMCH-B-128)"],"award-info":[{"award-number":["(2022-PUMCH-B-128)"]}]},{"name":"National High Level Hospital Clinical Research Funding of PUMCH","award":["(2022-PUMCH-B-128)"],"award-info":[{"award-number":["(2022-PUMCH-B-128)"]}]},{"name":"National High Level Hospital Clinical Research Funding of PUMCH","award":["(2022-PUMCH-B-128)"],"award-info":[{"award-number":["(2022-PUMCH-B-128)"]}]},{"name":"National High Level Hospital Clinical Research Funding of PUMCH","award":["(2022-PUMCH-B-128)"],"award-info":[{"award-number":["(2022-PUMCH-B-128)"]}]},{"name":"National High Level Hospital Clinical Research Funding of PUMCH","award":["(2022-PUMCH-B-128)"],"award-info":[{"award-number":["(2022-PUMCH-B-128)"]}]},{"name":"National High Level Hospital Clinical Research Funding of PUMCH","award":["(2022-PUMCH-B-128)"],"award-info":[{"award-number":["(2022-PUMCH-B-128)"]}]},{"name":"National High Level Hospital Clinical Research Funding of PUMCH","award":["(2022-PUMCH-B-128)"],"award-info":[{"award-number":["(2022-PUMCH-B-128)"]}]},{"name":"National High Level Hospital Clinical Research Funding of PUMCH","award":["(2022-PUMCH-B-128)"],"award-info":[{"award-number":["(2022-PUMCH-B-128)"]}]},{"name":"National High Level Hospital Clinical Research Funding of PUMCH","award":["(2022-PUMCH-B-128)"],"award-info":[{"award-number":["(2022-PUMCH-B-128)"]}]},{"name":"National High Level Hospital Clinical Research Funding of PUMCH","award":["(2022-PUMCH-B-128)"],"award-info":[{"award-number":["(2022-PUMCH-B-128)"]}]},{"name":"National High Level Hospital Clinical Research Funding of PUMCH","award":["(2022-PUMCH-B-128)"],"award-info":[{"award-number":["(2022-PUMCH-B-128)"]}]},{"name":"National High Level Hospital Clinical Research Funding of PUMCH","award":["(2022-PUMCH-B-128)"],"award-info":[{"award-number":["(2022-PUMCH-B-128)"]}]},{"name":"National High Level Hospital Clinical Research Funding of PUMCH","award":["(2022-PUMCH-B-128)"],"award-info":[{"award-number":["(2022-PUMCH-B-128)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04129-6","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T15:31:43Z","timestamp":1752593503000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Local\u2013regional therapy combined with immune checkpoint inhibitors and lenvatinib versus immune checkpoint inhibitors plus chemotherapy in advanced intrahepatic cholangiocarcinoma: a multicenter cohort study"],"prefix":"10.1007","volume":"74","author":[{"given":"Shuofeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanhua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjian","family":"Piao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Xun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiongyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongliang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"4129_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","volume":"7","author":"PJ Brindley","year":"2021","unstructured":"Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, Teh BT, Wongkham S, Gores GJ (2021) Cholangiocarcinoma. Nat Rev Dis Primers 7:65. https:\/\/doi.org\/10.1038\/s41572-021-00300-2","journal-title":"Nat Rev Dis Primers"},{"key":"4129_CR2","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","volume":"71","author":"P Bertuccio","year":"2019","unstructured":"Bertuccio P, Malvezzi M, Carioli G, Hashim D, Boffetta P, El-Serag HB, La Vecchia C, Negri E (2019) Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol 71:104\u2013114. https:\/\/doi.org\/10.1016\/j.jhep.2019.03.013","journal-title":"J Hepatol"},{"key":"4129_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"4129_CR4","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jhep.2022.10.021","volume":"78","author":"C Sposito","year":"2023","unstructured":"Sposito C, Ratti F, Cucchetti A et al (2023) Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node-negative intrahepatic cholangiocarcinoma. J Hepatol 78:356\u2013363. https:\/\/doi.org\/10.1016\/j.jhep.2022.10.021","journal-title":"J Hepatol"},{"key":"4129_CR5","doi-asserted-by":"publisher","first-page":"559","DOI":"10.14218\/JCTH.2021.00007","volume":"9","author":"R Xue","year":"2021","unstructured":"Xue R, Li R, Wang J, Tong W, Hao J (2021) Horizons on the therapy of biliary tract cancers: a state-of-the-art review. J Clin Transl Hepatol 9:559\u2013567. https:\/\/doi.org\/10.14218\/JCTH.2021.00007","journal-title":"J Clin Transl Hepatol"},{"key":"4129_CR6","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","volume":"7","author":"JW Valle","year":"2017","unstructured":"Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX (2017) New horizons for precision medicine in biliary tract cancers. Cancer Discov 7:943\u2013962. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0245","journal-title":"Cancer Discov"},{"key":"4129_CR7","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"D-Y Oh","year":"2022","unstructured":"Oh D-Y, Ruth He A, Qin S et al (2022) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 1:EVIDoa2200015. https:\/\/doi.org\/10.1056\/EVIDoa2200015","journal-title":"NEJM Evid"},{"key":"4129_CR8","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C et al (2023) Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401:1853\u20131865. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4","journal-title":"Lancet"},{"key":"4129_CR9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3322\/caac.21759","volume":"73","author":"D Moris","year":"2023","unstructured":"Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME (2023) Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin 73:198\u2013222. https:\/\/doi.org\/10.3322\/caac.21759","journal-title":"CA Cancer J Clin"},{"key":"4129_CR10","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273\u20131281. https:\/\/doi.org\/10.1056\/NEJMoa0908721","journal-title":"N Engl J Med"},{"key":"4129_CR11","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca A, Palmer DH, Wasan HS et al (2021) Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol 22:690\u2013701. https:\/\/doi.org\/10.1016\/S1470-2045(21)00027-9","journal-title":"Lancet Oncol"},{"key":"4129_CR12","doi-asserted-by":"publisher","first-page":"414","DOI":"10.21037\/hbsn-20-338","volume":"9","author":"J Lin","year":"2020","unstructured":"Lin J, Yang X, Long J et al (2020) Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. Hepatobiliary Surg Nutr 9:414\u2013424. https:\/\/doi.org\/10.21037\/hbsn-20-338","journal-title":"Hepatobiliary Surg Nutr"},{"key":"4129_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00262-024-03841-z","volume":"73","author":"S Wang","year":"2024","unstructured":"Wang S, Chao J, Wang H et al (2024) Effectiveness, safety, and biomarker analysis of lenvatinib plus toripalimab as chemo-free therapy in advanced intrahepatic cholangiocarcinoma: a real-world study. Cancer Immunol Immunother 73:249. https:\/\/doi.org\/10.1007\/s00262-024-03841-z","journal-title":"Cancer Immunol Immunother"},{"key":"4129_CR14","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1007\/s00262-023-03523-2","volume":"72","author":"J Chao","year":"2023","unstructured":"Chao J, Wang S, Wang H et al (2023) Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis. Cancer Immunol Immunother 72:3717\u20133726. https:\/\/doi.org\/10.1007\/s00262-023-03523-2","journal-title":"Cancer Immunol Immunother"},{"key":"4129_CR15","doi-asserted-by":"publisher","first-page":"894407","DOI":"10.3389\/fphar.2022.894407","volume":"13","author":"L Xie","year":"2022","unstructured":"Xie L, Huang J, Wang L et al (2022) Lenvatinib combined with a PD-1 inhibitor as effective therapy for advanced intrahepatic cholangiocarcinoma. Front Pharmacol 13:894407. https:\/\/doi.org\/10.3389\/fphar.2022.894407","journal-title":"Front Pharmacol"},{"key":"4129_CR16","doi-asserted-by":"publisher","first-page":"946861","DOI":"10.3389\/fimmu.2022.946861","volume":"13","author":"C Shi","year":"2022","unstructured":"Shi C, Li Y, Yang C et al (2022) Lenvatinib plus programmed cell death protein-1 inhibitor beyond first-line systemic therapy in refractory advanced biliary tract cancer: a real-world retrospective study in China. Front Immunol 13:946861. https:\/\/doi.org\/10.3389\/fimmu.2022.946861","journal-title":"Front Immunol"},{"key":"4129_CR17","doi-asserted-by":"publisher","first-page":"751391","DOI":"10.3389\/fonc.2021.751391","volume":"11","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Liu X, Wei S, Zhang L, Tian Y, Gao Z, Jin M, Yan S (2021) Lenvatinib plus PD-1 inhibitors as first-line treatment in patients with unresectable biliary tract cancer: a single-arm, open-label, phase II study. Front Oncol 11:751391. https:\/\/doi.org\/10.3389\/fonc.2021.751391","journal-title":"Front Oncol"},{"key":"4129_CR18","doi-asserted-by":"publisher","first-page":"112492","DOI":"10.1016\/j.intimp.2024.112492","volume":"137","author":"B Pang","year":"2024","unstructured":"Pang B, Zuo B, Huang L et al (2024) Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma. Int Immunopharmacol 137:112492. https:\/\/doi.org\/10.1016\/j.intimp.2024.112492","journal-title":"Int Immunopharmacol"},{"key":"4129_CR19","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.immuni.2018.03.007","volume":"48","author":"SA Patel","year":"2018","unstructured":"Patel SA, Minn AJ (2018) Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies. Immunity 48:417\u2013433. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.007","journal-title":"Immunity"},{"key":"4129_CR20","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","volume":"16","author":"AB Sharabi","year":"2015","unstructured":"Sharabi AB, Lim M, DeWeese TL, Drake CG (2015) Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol 16:e498\u2013e509. https:\/\/doi.org\/10.1016\/S1470-2045(15)00007-8","journal-title":"Lancet Oncol"},{"key":"4129_CR21","first-page":"1026","volume":"13","author":"Y Wang","year":"2023","unstructured":"Wang Y, Xun Z, Yang X et al (2023) Local-regional therapy combined with toripalimab and lenvatinib in patients with advanced biliary tract cancer. Am J Cancer Res 13:1026\u20131037","journal-title":"Am J Cancer Res"},{"key":"4129_CR22","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1007\/s00262-023-03399-2","volume":"72","author":"Y Wang","year":"2023","unstructured":"Wang Y, Yang X, Wang Y et al (2023) Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world study. Cancer Immunol Immunother 72:2197\u20132204. https:\/\/doi.org\/10.1007\/s00262-023-03399-2","journal-title":"Cancer Immunol Immunother"},{"key":"4129_CR23","doi-asserted-by":"publisher","first-page":"1084843","DOI":"10.3389\/fimmu.2023.1084843","volume":"14","author":"Y Wang","year":"2023","unstructured":"Wang Y, Zhang N, Xue J et al (2023) Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC. Front Immunol 14:1084843. https:\/\/doi.org\/10.3389\/fimmu.2023.1084843","journal-title":"Front Immunol"},{"key":"4129_CR24","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejca.2016.03.082","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Seymour L, Liti\u00e8re S et al (2016) RECIST 1.1 - Standardisation and disease-specific adaptations: perspectives from the RECIST working group. Eur J Cancer 62:138\u2013145. https:\/\/doi.org\/10.1016\/j.ejca.2016.03.082","journal-title":"Eur J Cancer"},{"key":"4129_CR25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the Common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed) 112:90\u201392. https:\/\/doi.org\/10.1016\/j.ad.2019.05.009","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"4129_CR26","doi-asserted-by":"publisher","first-page":"907055","DOI":"10.3389\/fonc.2022.907055","volume":"12","author":"X Ding","year":"2022","unstructured":"Ding X, Li G, Sun W, Shen Y, Teng Y, Xu Y, Li W, Liu M, Chen J (2022) Sintilimab combined with lenvatinib for advanced intrahepatic cholangiocarcinoma in second-line setting-a multi-center observational study. Front Oncol 12:907055. https:\/\/doi.org\/10.3389\/fonc.2022.907055","journal-title":"Front Oncol"},{"key":"4129_CR27","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/15384047.2020.1834792","volume":"22","author":"Q Zhao","year":"2021","unstructured":"Zhao Q, Chen Y, Du S, Yang X, Chen Y, Ji Y, Zeng Z (2021) Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar cholangiocarcinoma: reflection from four cases. Cancer Biol Ther 22:175\u2013183. https:\/\/doi.org\/10.1080\/15384047.2020.1834792","journal-title":"Cancer Biol Ther"},{"key":"4129_CR28","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s40425-019-0692-z","volume":"7","author":"X Liu","year":"2019","unstructured":"Liu X, Yao J, Song L, Zhang S, Huang T, Li Y (2019) Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade. J Immunother Cancer 7:204. https:\/\/doi.org\/10.1186\/s40425-019-0692-z","journal-title":"J Immunother Cancer"},{"key":"4129_CR29","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3389\/fmed.2020.00368","volume":"7","author":"Z-L Liu","year":"2020","unstructured":"Liu Z-L, Liu X, Peng H, Peng Z-W, Long J-T, Tang D, Peng S, Bao Y, Kuang M (2020) Anti-PD-1 immunotherapy and radiotherapy for stage IV intrahepatic cholangiocarcinoma: a case report. Front Med (Lausanne) 7:368. https:\/\/doi.org\/10.3389\/fmed.2020.00368","journal-title":"Front Med (Lausanne)"},{"key":"4129_CR30","first-page":"3455","volume":"12","author":"T Zhang","year":"2022","unstructured":"Zhang T, Yang X, Yang X et al (2022) Different interventional time of hepatic arterial infusion with PD-1 inhibitor for advanced biliary tract cancer: a multicenter retrospective study. Am J Cancer Res 12:3455\u20133463","journal-title":"Am J Cancer Res"},{"key":"4129_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.940009","volume":"13","author":"X-G Yang","year":"2022","unstructured":"Yang X-G, Sun Y-Y, Li D-S, Xu G-H, Huang X-Q (2022) Efficacy and safety of drug-eluting beads transarterial chemoembolization combining immune checkpoint inhibitors in unresectable intrahepatic cholangiocarcinoma: a propensity score matching analysis. Front Immunol 13:940009. https:\/\/doi.org\/10.3389\/fimmu.2022.940009","journal-title":"Front Immunol"},{"key":"4129_CR32","doi-asserted-by":"publisher","first-page":"111642","DOI":"10.1016\/j.intimp.2024.111642","volume":"129","author":"T Zhang","year":"2024","unstructured":"Zhang T, Zhu C, Zhang N et al (2024) Lenvatinib combined with PD-1 inhibitor plus Gemox chemotherapy versus plus HAIC for advanced biliary tract cancer. Int Immunopharmacol 129:111642. https:\/\/doi.org\/10.1016\/j.intimp.2024.111642","journal-title":"Int Immunopharmacol"},{"key":"4129_CR33","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/1751-2980.13127","volume":"23","author":"N Zhang","year":"2022","unstructured":"Zhang N, Yu BR, Wang YX et al (2022) Clinical outcomes of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and anti-PD-1 immunotherapy for unresectable intrahepatic cholangiocarcinoma. J Dig Dis 23:535\u2013545. https:\/\/doi.org\/10.1111\/1751-2980.13127","journal-title":"J Dig Dis"},{"key":"4129_CR34","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/jnci\/djz071","volume":"112","author":"A Lamarca","year":"2020","unstructured":"Lamarca A, Ross P, Wasan HS et al (2020) Advanced intrahepatic cholangiocarcinoma: post hoc analysis of the ABC-01, -02, and -03 clinical trials. J Natl Cancer Inst 112:200\u2013210. https:\/\/doi.org\/10.1093\/jnci\/djz071","journal-title":"J Natl Cancer Inst"},{"key":"4129_CR35","doi-asserted-by":"publisher","first-page":"1210673","DOI":"10.3389\/fonc.2023.1210673","volume":"13","author":"T Li","year":"2023","unstructured":"Li T, Qian X, Liu J et al (2023) Radiotherapy plus immune checkpoint inhibitor in prostate cancer. Front Oncol 13:1210673. https:\/\/doi.org\/10.3389\/fonc.2023.1210673","journal-title":"Front Oncol"},{"key":"4129_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242316691","author":"SH Jeon","year":"2023","unstructured":"Jeon SH, Song C, Eom K-Y, Kim IA, Kim J-S (2023) Modulation of CD8+ T cell responses by radiotherapy-current evidence and rationale for combination with immune checkpoint inhibitors. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms242316691","journal-title":"Int J Mol Sci"},{"key":"4129_CR37","doi-asserted-by":"publisher","first-page":"e352","DOI":"10.1016\/S1470-2045(24)00075-5","volume":"25","author":"C Lynch","year":"2024","unstructured":"Lynch C, Pitroda SP, Weichselbaum RR (2024) Radiotherapy, immunity, and immune checkpoint inhibitors. Lancet Oncol 25:e352\u2013e362. https:\/\/doi.org\/10.1016\/S1470-2045(24)00075-5","journal-title":"Lancet Oncol"},{"key":"4129_CR38","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/sj.bjc.6605465","volume":"102","author":"WM Liu","year":"2010","unstructured":"Liu WM, Fowler DW, Smith P, Dalgleish AG (2010) Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer 102:115\u2013123. https:\/\/doi.org\/10.1038\/sj.bjc.6605465","journal-title":"Br J Cancer"},{"key":"4129_CR39","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.2147\/CMAR.S188316","volume":"11","author":"M Capozzi","year":"2019","unstructured":"Capozzi M, De Divitiis C, Ottaiano A, von Arx C, Scala S, Tatangelo F, Delrio P, Tafuto S (2019) Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment. Cancer Manag Res 11:3847\u20133860. https:\/\/doi.org\/10.2147\/CMAR.S188316","journal-title":"Cancer Manag Res"},{"key":"4129_CR40","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.4251\/wjgo.v16.i7.3256","volume":"16","author":"Y Guo","year":"2024","unstructured":"Guo Y, Li R-C, Xia W-L, Yang X, Zhu W-B, Li F-T, Hu H-T, Li H-L (2024) Immune effect and prognosis of transcatheter arterial chemoembolization and tyrosine kinase inhibitors therapy in patients with hepatocellular carcinoma. World J Gastrointest Oncol 16:3256\u20133269. https:\/\/doi.org\/10.4251\/wjgo.v16.i7.3256","journal-title":"World J Gastrointest Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04129-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04129-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04129-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T19:03:20Z","timestamp":1754334200000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04129-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":40,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["4129"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04129-6","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study complied with the Declaration of Helsinki and obtained ethical approvals from ethics committees of PUMCH (No. I-24PJ2728, I-24PJ2729), NCC (No. 25\/138\u20135084), PLAGH (No. KY-2025\u20131-18\u20131), and CJFH (No. 2025-KY-143). Informed consent was exempted by these committees under the retrospective protocol.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"271"}}